responsible for the proliferation of Cyld-deficient keratinocytes can be examined in Bcl-3-deficient mice following TPA and UV stimulation. The authors already indicate such a possibility by showing that the depletion of Bcl-3 by small interfering RNA reduced cyclin D1 promoter activation induced by TPA and reversed the increased proliferation rate of Cyld-deficient keratinocytes.
Interestingly, a recent report by Reiley et al. (2006) describes a new regulatory role for CYLD in T cell receptor (TCR) signaling. Cyld-deficient mice are impaired in thymocyte development due to aberrations in the transition of double-positive to single-positive T cells. Contrary to the finding in keratinocytes, there are no defects in TNF-receptor-induced NF-κB signaling in bone-marrowderived macrophages of Cyld-deficient mice. The fact that there are differences in CYLD function in thymocytes and keratinocytes points to receptor-specific and cell-type-specific functions of CYLD. The regulation of CYLD deubiquitinating activity, which is not completely understood, awaits further experimental confirmation in distinct cell types. At the same time, the understanding of keratinocyte-specific signaling mediated by CYLD provides a greater opportunity to develop therapeutic agents for cylindromatosis. Potential agents include nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and natural compounds (e.g., ginseng extract and green-tea extract), all of which can inhibit activation of NF-κB. These anti-inflammatory agents and CYLD have a similar effect on NF-κB signaling, even though they act on different targets in the pathway. Topical application of aspirin has already entered clinical trials for the treatment of cylindromatosis. It is worth testing whether aspirin's efficacy in treating cylindromatosis depends on interfering with the Bcl-3 pathway as well. This study and the excitement in the field of NF-κB and cancer pathogenesis promise to foster the design of better therapeutics for cylindromatosis patients.
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Franzoso, G., Carlson, L., Scharton-Kersten, T., Shores, E.W., Epstein, S., Grinberg, A., Tran, T., Shacter, E., Leonardi, A., Anver, M., et al. (1997) Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., and Mosialos, G. (Lim et al., 2006) . This study shows that many proteins associated with ataxias share common interacting protein partners. The results prospectively identify new candidate genes for inherited ataxias. The Lim et al. study was motivated by the observation that although several inherited cerebellar ataxias share clinical and pathological features, they are caused by diverse mutations in unrelated genes. There are two groups of hereditary ataxias (Taroni and DiDonato, 2004) . Recessive ataxias are caused by mutations that lead to a loss of protein function. In contrast, most dominant ataxias are caused by an expansion of CAG triplet repeats in the coding region of disease genes, resulting in production of a protein with an abnormal polyglutamine (polyQ) expansion. In their yeast two-hybrid screen, Lim et al. (2006) used human proteins from three categories as bait: proteins that when mutated are directly involved in ataxias, proteins that interact with ataxia-causing proteins, and paralogs of such proteins. The screen revealed 770 protein-protein interactions that were subsequently assembled into a network along with relevant protein-protein interactions curated from the literature. Strikingly, this protein-protein interaction network is markedly different from a control network that was assembled using a similar number of disease proteins from a group of disorders with diverse phenotypes. The ataxia interactome network is enriched for proteins involved in processes thought to be important in several inherited ataxias. These processes include DNA repair and maintenance, transcription, RNA processing, and protein quality control and recycling.
Zoghbi and colleagues have identified connections between different proteins that, when mutated, cause ataxias. In addition to dominant ataxias, polyQ expansions are also found in noncerebellar disorders such as Huntington's disease (HD). One question that arises is whether we can expand some of the proteinprotein interactions identified in the ataxia network to help identify the interacting partners of other polyQcontaining proteins. Indeed, the observation that the same mutation in different proteins can cause neuronal death suggests that some pathogenic mechanisms could be shared by these disorders. In particular, in both HD and the cerebellar ataxias the polyQ-containing proteins must be localized to the nucleus for the pathogenic process to occur, and in both cases a dysregulation of the transcriptional machinery is involved. Interestingly, if one compares the previously published interactome for huntingtin (which is the protein mutated in Huntington's disease) (Goehler et al., 2004) with the new ataxia interactome (Lim et al., 2006) , several nuclear proteins appear repeatedly, including the TATA binding protein (TBP) and p53, which are both important transcriptional regulators. PolyQ expansions in TBP are associated with the spinocerebellar ataxia, SCA17. However, some abnormal polyQ expansions in TBP are also found in patients clinically diagnosed with HD but who do not have the polyQ expansion in the huntingtin protein (Stevanin et al., 2003) . This observation further supports the notion that mutation in functionally related proteins may generate similar phenotypes in patients.
Given what is shared among these disorders, what makes them different from one another? The commonly accepted theory for the polyQ diseases is that the polyQ expansion in different proteins leads to the death of a different subset of neurons depending on the disease. However, when carefully analyzed, juvenile HD patients with highly expanded stretches of polyQ in the huntingtin protein also develop ataxia and show cerebellar degeneration. This suggests that when the number of glutamine repeats goes above a certain threshold, the specificity between these disorders is lost. Perhaps above this threshold the protein-protein interactions become less specific, which leads to interactions that are detrimental to the survival of all neurons not just a specific subset. Below this threshold, the pathology of each disease may be driven by protein-protein interactions specific to the context of the disease protein, thereby leading to cell death of a particular neuronal type. In support of this idea, posttranslational modifications (such as phosphorylation) that are outside the polyQ stretch in some of these proteins are sufficient to abrogate their toxicity. This finding strengthens the rationale underpinning Lim et al.'s protein-protein interaction study and raises the question of whether short protein fragments with large polyQ repeats should be used to model these diseases. Lim et al. (2006) demonstrate that genes and proteins causing the same or related diseases may interact with or be part of the same pathway. This may also be true of neurodegenerative disorders that affect other brain regions, such as Parkinson's disease (PD), which stems from the loss of dopaminergic neurons in the substantia nigra. Mutations in several genes responsible for sporadic and familial forms of PD result in similar phenotypes. The first and best studied are the genes for α-synuclein and parkin. Mutations in α-synuclein and parkin lead to dominant and recessive forms of PD, respectively. Interestingly, there is a clear connection between the two proteins. Parkin ubiquitinates the α-synuclein-interacting protein synphilin-1 and/or a glycosylated form of α-synuclein, thus participating in the formation of Lewy bodies, the protein aggregates frequently seen in the brains of PD patients (Chung et al., 2001; Shimura et al., 2001 ). More recently, parkin has been shown to interact with the leucine-rich repeat kinase-2 (LRRK2), a kinase that is mutated in an autosomal dominant form of PD (Smith et al., 2005) . From these two examples, it appears that mutations in proteins belonging to the same functional network may be responsible for diseases that share similar clinical presentations. It is therefore tempting to speculate that building a protein-protein interaction network from proteins that cause PD may help to identify mutations that are responsible for other sporadic and familial forms of the disease and could lead to the identification of new susceptibility genes.
Several types of protein-protein interaction maps have been developed. These include specific interaction networks, such as the ataxia network presented by Lim et al. (2006) , which generate a huge number of gene modifier candidates that may participate in or regulate pathogenic processes. Other networks have described interactions across the entire proteome in model organisms such as yeast, Drosophila, and Caenorhabditis elegans. Approaches to systematically map human protein interactions have also been undertaken (Rual et al., 2005; Stelzl et al., 2005) . These networks are certainly not independent and should be considered together as they will contribute in a complementary manner to understanding the mechanisms that control cellular behavior in development and disease. Indeed, thousands of interactions have been described, and now the challenge is to conduct comparative analysis of these interactomes to organize these data. We also need to further address the dynamics of these systems. Thus, it will be critical to determine when and where these interactions occur and how they are regulated both within a given cell and in the context of whole tissues.
Validating therapeutic targets is an inherently difficult undertaking. The sheer number of potential drug targets in the postgenomic era makes validation the rate-limiting step in drug development (Lindsay, 2003) . Not surprisingly, many more therapeutic candidates fail because of a lack of efficacy rather than because of safety concerns. Owing to the astronomical costs of drug development, a high threshold is set for the validation of new drug targets. The ideal drug target is one whose inhibition leads to the desired therapeutic outcome and does not lead to deleterious so-called mechanism-based side effects. Mechanism-based side effects arise from the inhibition of the normal function of an enzyme, which is separate from its disease-associated function. But for any given target, the likelihood of a simple pharmacological landscape with no off-target activity due to inhibition of homologous proteins and no mechanismbased side effects is low. However,
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